Richard M. Lush

Moffitt Cancer Center — United States

Medicine · Health Sciences

30h-index4.2kcitations103works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Treatment and Pharmacology(20), Cancer therapeutics and mechanisms(20), Prostate Cancer Treatment and Research(11), Lung Cancer Research Studies(11), Lung Cancer Treatments and Mutations(10)

Publications102 total

Data from Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
2023Open Access
Supplementary Data from Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
2023Open Access
Supplementary Methods and Table 1 from Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates
2023Open Access
Data from Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates
2023Open Access
Data from Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
2023Open Access
Data from Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates
2023Open Access
Supplementary Data from Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
2023Open Access
Supplementary Methods and Table 1 from Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with Autologous Stem Cell Transplant in Refractory Cancer: Pharmacokinetic and Pharmacodynamic Correlates
2023Open Access
Table of Contents
Clinical Breast Cancer·2022Open Access
A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC)
Clinical Breast Cancer·2021· 32 citedOpen Access
Phase II Study of the Mitogen-Activated Protein Kinase 1/2 Inhibitor Selumetinib in Patients With Advanced Hepatocellular Carcinoma
UNC Libraries·2020Open Access
A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG‐asparaginase, and doxorubicin
Pediatric Blood & Cancer·2018· 34 cited
A phase I study of indoximod in patients with advanced malignancies
Oncotarget·2016· 141 citedOpen Access
Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies
Cancer Medicine·2015· 15 citedOpen Access
A Phase I Safety, Pharmacokinetic, and Pharmacodynamic Presurgical Trial of Vitamin E δ-tocotrienol in Patients with Pancreatic Ductal Neoplasia
EBioMedicine·2015· 79 citedOpen Access
Pharmacokinetics, safety, and tolerability of a new patritumab formulation in patients with advanced, refractory solid tumors.
Journal of Clinical Oncology·2015· 8 cited
Effect of Age on Clinical Outcomes in Phase 1 Trial Participants
Cancer Control·2015· 17 cited
Clinical outcomes of patients with gastrointestinal malignancies participating in phase I clinical trials.
Journal of Clinical Oncology·2015
Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: Model prediction and clinical confirmation
The Journal of Clinical Pharmacology·2014· 5 cited
A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
Clinical Cancer Research·2014· 58 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

William D. Figg(13), Anthony Neuger(11), Daniel M. Sullivan(11), Donna Headlee(7), Edward A. Sausville(6), Alberto Chiappori(6), William D. Figg(6), Adrian M. Senderowicz(5), Eddie Reed(5), Mayer Fishman(4), Scott Antonia(4), Seth M. Steinberg(4), A Tompkins(4), Kenneth S. Bauer(4), Pamela N. Münster(4), George R. Simon(4), Susan Minton(4), Saı̈d M. Sebti(4), Susan G. Arbuck(3), Adil Daud(3)